Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

被引：0

作者：

Fanale, Michelle A. ^{[1
]}

Wang, Zhiqiang ^{[1
]}

Ma, Wencai ^{[1
]}

Oki, Yasuhiro ^{[1
]}

Hagemeister, Fredrick B. ^{[1
]}

Fayad, Luis E. ^{[1
]}

Fowler, Nathan ^{[1
]}

Romaguera, Jorge E. ^{[1
]}

Shah, Nina ^{[2
]}

Chuang, Hubert H. ^{[3
]}

Lei, Feng ^{[4
]}

Horowitz, Sandra B. ^{[5
]}

Chihara, Dai ^{[1
]}

Wesson, Emily ^{[1
]}

Hutto, Toni Y. ^{[1
]}

Ruben, Charnelle ^{[1
]}

Samaniego, Felipe ^{[1
]}

Muzzafar, Tariq ^{[6
]}

Piekarz, Richard ^{[7
]}

Davis, R. Eric ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Pharm, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[7] NCI, Canc Therapeut Evaluat Program, Bethesda, MD 20892 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] Gene expression profiling of peripheral T-cell lymphomas not otherwise characterized reveals molecular signatures related to survival
Cuadros Celorrio, Marta
Honrado, Emiliano
Milne, Roger
Alves Ferreira, Javier
Benitez, Javier
Martinez-Delgado, Beatriz
CANCER RESEARCH, 2006, 66 (08)
[42] Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas
Lemoine, Jean
Morin, Florence
Di Blasi, Roberta
Vercellino, Laetitia
Cuffel, Alexis
Benlachgar, Naoufal
Larghero, Jerome
Madelaine, Isabelle
Calvani, Julien
Meignin, Veronique
Caillat-Zucman, Sophie
Chevret, Sylvie
BLOOD, 2021, 138
[43] Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)
Friedberg, Jonathan
Mahadevan, Daruka
Jung, JungAh
Persky, Daniel O.
Lossos, Izidore S.
Danaee, Hadi
Zhou, Xiaofei
Leonard, E. Jane
Bernstein, Steven H.
BLOOD, 2011, 118 (21) : 46 - 46
[44] Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial
Xu, Wei
Liang, Jin-Hua
Wang, Li
Wang, Xiao-Dong
Cui, Guohui
Zhou, Jianfeng
Xu, Jingyan
Wang, Luqun
Liang, Rong
Chen, Bi-yun
Cheng, Jian
Li, Jian-Yong
BLOOD, 2022, 140 : 9484 - 9485
[45] A Multicenter Phase I Dose-Finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin in Combination with Pegylated Liposomal Doxorubicin for the Treatment of Adults with Relapsed or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Ai, Weiyun
Porcu, Pierluigi
Berry, Wade
Engleman, Juliana
Wieduwilt, Matthew J.
Brammer, Jonathan E.
BLOOD, 2017, 130
[46] Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Yamasaki, Satoshi
Iida, Hiroatsu
Saito, Akio
Matsumoto, Morio
Kuroda, Yoshiaki
Izumi, Tohru
Saito, Akiko M.
Miyoshi, Hiroaki
Ohshima, Koichi
Nagai, Hirokazu
Iwasaki, Hiromi
HEMATOLOGY REPORTS, 2024, 16 (02) : 336 - 346
[47] Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL)
Evens, Andrew M.
Gordon, Leo I.
Patton, David
Rosen, Steven T.
Winter, Jane N.
Kline, Justin
Van Besien, Koen
Smith, Sonali M.
BLOOD, 2008, 112 (11) : 700 - 700
[48] Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study
Iyer, Swaminathan P.
Huen, Auris
Ai, Weiyun Z.
Jagadeesh, Deepa
Lechowicz, Mary J.
Okada, Craig
Feldman, Tatyana A.
Ghione, Paola
Alderuccio, Juan P.
Champion, Rebecca
Kim, Seo-Hyun
Mohrbacher, Ann
Routhu, Kasi, V
Barde, Prajak
Nair, Ajit M.
Haverkos, Bradley M.
HAEMATOLOGICA, 2024, 109 (01) : 209 - 219
[49] Liposomal tretinoin: Promising early results of an ongoing phase II trial in relapsed or refractory non-Hodgkin's lymphomas (NHL) and cutaneous T-cell lymphomas (CTCL).
Sarris, AH
Hagemeister, F
McLaughlin, P
Rodriguez, MA
Pro, B
Romaguera, J
Zipf, T
Mesina, O
Medeiros, LJ
Oholendt, M
Lopez-Berenstein, G
Ford, R
Williams, T
Cabanillas, F
BLOOD, 2000, 96 (11) : 136A - 136A
[50] Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
Godfrey, James
Mei, Matthew
Chen, Lu
Song, Joo Y.
Bedell, Victoria
Budde, L. Elizabeth
Armenian, Saro
Puverel, Sandrine
Nikolaenko, Liana
Chen, Robert
Daniels, Shari
Kennedy, Neena
Peters, Lacolle
Rosen, Steven T.
Forman, Stephen J.
Popplewell, Leslie L.
Kwak, Larry W.
Herrera, Alex F.
HAEMATOLOGICA, 2024, 109 (02) : 533 - 542

← 1 2 3 4 5 →